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ABSTRACT
Stress activates the autonomic nervous system (ANS) and the hypothalamic–pituitary–adrenal axis
(HPAA). Based on a systematic literature review of the impact of endogenous and exogenous exposure
with natural progesterone on the stress response in healthy premenopausal and postmenopausal
women, the following conclusions can be drawn: the HPAA activity was not relevantly affected by
endogenous progesterone exposure across the menstrual cycle, but might be reduced by exogenous
micronized progesterone application; in contrast, the ANS has a sympathetic predominance in the
(progesterone-dominated) luteal phase of the menstrual cycle. Future studies should assess various
stress biomarkers under various hormonal conditions to, for example, allow for cardiovascular risk
stratification in hormone users.
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Introduction
Stress is the body’s response to intrinsic or extrinsic positive or
negative challenging factors. Acute stress reactions last for
minutes or hours, whereas chronic stress is defined as mal-
adjustment to repeatedly occurring stressors due to
the absence of appropriate coping mechanisms1 lasting
for days to months2. Stressors activate the autonomic nervous
system (ANS) and hypothalamic–pituitary–adrenal axis (HPAA)3.
Non-invasive measurement of heart rate variability (HRV) –
that is, the ongoing beat-to-beat variation of cyclic heart
activity4 – is an established method to assess the autonomic
balance5 and to characterize ANS reactivity6. Reduced HRV
implies less ANS adaptability and has been found to be asso-
ciated with increased cardiovascular disease morbidity7 and
mortality8. Both elevated sympathetic and decreased para-
sympathetic activity tend to aggravate arrhythmias leading
to death9. There are two common ways to measure HRV:
time domain analysis and frequency domain analysis
(Tables 1 and 2)10.
Cortisol is the executive hormone after HPAA stimulation
aiming to provide sufficient energy to overcome stress fac-
tors11 by, for example, encouraging catabolic pathways as
proteolysis and lipolysis, raising plasma concentrations of
glucose, free fatty acid, and insulin12, and modulating the
immune system13. Cortisol levels can be measured in plasma,
serum, saliva, and urine. The unbound cortisol fraction repre-
sents the physiological reactive cortisol amount. Unbound
salivary and urinary cortisol levels are strongly correlated and
better represent adrenocortical function than the total corti-
sol serum level, which mainly represents protein-bound corti-
sol11,14. In contrast, approximately only 14% of salivary and
1% of urinary cortisol is protein bound11.
Especially, chronic stress exposure is associated with an
increased risk for several chronic non-communicable diseases
such as cardiovascular diseases15, gastrointestinal diseases16,
diabetes mellitus, osteoporosis, immunodeficiency17, sleep-
ing disorders18, and chronic pain19. In women, the non-
communicable disease risk also increases after menopause
and may be attenuated or even prevented by menopausal
hormone therapy (MHT)20. Indeed, endogenous sex hor-
mones have been shown to have an impact on the
ANS21–23 and the HPAA24. Similarly, in postmenopausal
women MHT has been found to beneficially modify the
stress response22,25.
The aim of this systematic review was to investigate the
impact of endogenous (menstrual cycle) and exogenous
(MHT containing micronized progesterone [MP]) progester-
one (P) exposure on stress biomarkers, cortisol, and HRV,
respectively.
Materials and methods
In November 2018, a systematic literature search was
performed using the Medline database (PubMed). Only
articles in English and studies in humans were included.
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As MP has been available in Europe since 198026 and
worldwide since 198627, only articles published after 1980
were included. For each topic – that is, impact of endogen-
ous P and exogenous MP on the HPAA and HRV – individ-
ual searches were performed using multiple combinations
of keywords, Mesh terms, and text words related to
the respective topic. For the first topic, included keywords
were the MeSH terms ‘corticotropin-releasing hormone’,
‘adrenocorticotropic hormone’, and ‘cortisol’ and its key-
words using the logical connection OR. The resulting hits
were connected to the MeSH terms ‘progesterone’,
‘hormone replacement therapy’, and ‘menstrual cycle’
and its keywords using the logical connection AND.
To restrict the number of hits to those with the highest sci-
entific evidence level, only meta-analyses, systematic
reviews, and randomized controlled trials (RCTs) were
included. For the second topic, the MeSH terms ‘heart rate
variability’ were linked with ‘progesterone’, ‘hormone
replacement therapy’, and ‘menstrual cycle’ and its key-
words using the logical connection AND. Assuming that
the review by von Holzen et al.22 was complete, only
articles published after 2015 were considered for all search
commands with ‘heart rate variability’. Exclusion criteria
were other medications expected for MHT not containing
MP that may influence the HPA or the ANS, respectively.
Similarly studies without clear identification of progestogen
type were excluded.
Results
Out of 321 hits, 41 articles fulfilled the inclusion and exclu-
sion criteria and were included in the review (Table 3).
Impact of progesterone on the
hypothalamic–pituitary–adrenal axis
Impact of endogenous progesterone exposure across the
menstrual cycle on the hypothalamic–pituitary–adre-
nal axis
Overall, 19 studies evaluated the impact of endogenous P
exposure across the menstrual cycle on the HPAA3,14,28–44
(Supplementary Table S1). Of those, 12 studies assessed
baseline HPAA serum level3,14,29,31–34,36–38,40,43, and 12 stud-
ies assessed HPAA reactivity after a challenge
test3,14,28–30,35,36,39,41–44. All but three articles were RCTs,
while two were systematic reviews31,43 and one was an
observational cohort study3. The sample size ranged from
five35 to 5629 subjects. Mean age ranged from 20.7 years38 to
36.6 years42, or was not clearly specified29,44. Participants
were neither pregnant nor users of hormonal contraceptives
and were generally healthy in all but two studies including
women with premenstrual syndrome (PMS)36,43 or premen-
strual dysphoric disorder (PMDD)42, respectively. One study
did not report subjects’ health condition34.
Assessments of the baseline HPAA serum level comprised
at least one cortisol serum sample during the follicular
phase and another during the luteal phase of the menstrual
cycle in most studies30,32,33,35,36,39–44. Others used salivary
cortisol28,29,33,34,37,43, urinary cortisol14,38,43, adrenocortico-
tropic hormone (ACTH) serum30,43, or corticotropin-
releasing hormone (CRH) samples31, respectively. Cortisol
levels were measured by various methods including radio-
immunoassay14,30,32,38–42,44, enzyme immunoassay3,28,29,33,37,
chemiluminescent immunoassay33,35, time-resolved fluoro-
metric immunoassay34, and solid-phase fluoroimmunoassay36.
ACTH and cortisol samples were mostly taken between 6:00
a.m. and 12:30 p.m.3,14,32,33,35,38,40,41,44, and others either in
the afternoon between 1:00 and 8:00 p.m.28–30,37,38 or along
Table 1. Selected time domain parameters of heart rate variability.
Parameter (unit) Description
SDNN (ms) Standard deviation of all normal sinus beat intervals9; representing the balance of sympathetic and parasympathetic activity, a
reduction implies a diminished vagal activity61
SDANN (ms) Standard deviation of the averages of normal sinus beat intervals in all 5-min segments along the whole
electrocardiogram recording9
SDNN index (ms) Mean of the standard deviations of all normal sinus beat intervals for all 5-min segments along the whole
electrocardiogram recording9
RMSSD (ms) The square root of the mean of the sum of the squared differences between adjoining normal sinus beat intervals9; reflecting the
parasympathetic part of autonomic nervous system61
NN50 count Number of pairs of adjoining normal sinus beat intervals deviating by more than 50ms along the whole recording9
pNN50 (%) NN50 count divided by the total number of all normal sinus beat intervals9; reflecting the parasympathetic part of autonomic
nervous system61
Table 2. Selected frequency domain parameters of heart rate variability.
Parameter (unit) Description
ULF (ms2) Power in ultra-low-frequency spectrum (0.003 Hz)9
VLF (ms2) Power in very-low-frequency spectrum (0.003–0.04 Hz)9
LF (ms2) Power in low-frequency spectrum (0.04–0.15 Hz)9; representing the sympathetic and parasympathetic influence62
LF norm (n.u.) Low-frequency power in normalized units9
HF (ms2) Power in high-frequency spectrum (0.15–0.4 Hz); representing the impact of parasympathetic part on the autonomic nervous system62
HF norm (n.u.) High-frequency power in normalized units9
LF/HF ratio Representing balance of sympathetic and parasympathetic activity63
Total power (ms2) Variance of all normal sinus beat intervals (approximately 0.4 Hz)9; reflecting the complete activity of the autonomic nervous system62
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the entire day34,38. The remaining studies did not describe
the exact time point of cortisol31,32,36,39,42,43 or CRH31 sam-
ple collection.
While CRH secretion has been reported to change across
the menstrual cycle displaying a CRH31 or ACTH45 peak,
respectively, around the time of ovulation, the majority of
studies did not observe a change of baseline cortisol
serum3,14,32–34,36,38,40,43, salivary14,34,38, and urinary14,38 levels
across the menstrual cycle. These findings support the earlier
systematic review from 199443 showing no impact of the
menstrual cycle on basal serum cortisol46–51 and serum ACTH
levels52. Some studies also showed no difference for the
menstrual cycle on basal urinary53 and serum45,54 cortisol
levels55 in women with PMS. However, others found higher
salivary29 and serum cortisol levels during the luteal than fol-
licular phase, or vice versa for salivary33,37 24-h urinary corti-
sol38. When comparing women with and without PMDD, the
mean values of serum cortisol levels were higher during
the follicular phase in women with PMDD and higher in the
luteal phase in controls40.
Twelve studies investigated the HPAA responsiveness to a
challenge test in relation to the menstrual cycle and yielded
conflicting results3,14,28–30,35,36,39,41–44.
In detail, five studies did not report any alterations in
HPAA responsiveness due to the menstrual cycle on urin-
ary14, salivary14, and serum cortisol30,35,41,44 and serum ACTH
levels30. In these studies, the following HPAA challenge tests
were applied: insulin tolerance test30, physical exercise14,35,
alcohol drink41, and different diets44. These findings support
the earlier systematic review from 199443 showing no impact
of the menstrual cycle on serum cortisol53,56, serum ACTH53,
and urinary cortisol57 responsiveness. The HPAA challenge
tests used were intravenous ovine CRH injection53, psycho-
neuroendocrine stress57, and physical exercise56.
In contrast, others reported a higher salivary28 and
serum39 cortisol stress response in the follicular phase as
compared to the luteal phase. In these studies, the Trier
Social Stress Test28, intravenous alcohol injection36, an alco-
hol drink42, or a certain diet39 were used as HPAA chal-
lenge tests.
Quite the opposite was observed by two studies29,39 using
either a cold pressor stress test29 or soy diet39 as the HPAA
challenge test, respectively. They found a higher salivary29
and serum39 cortisol stress response in the luteal phase as
compared to the follicular phase.
Bringing up one study in particular, Ohara et al.3 com-
pared salivary cortisol levels at baseline and after a 14-h fast
(fasting trial), respectively, after a 12-h fast followed by a
meal intake (meal intake trial) affected by menstrual cycle
phases. The data analysis showed higher baseline cortisol
levels in the luteal phase and different phase-related
enhancement dependent on the time point of sample collec-
tion in the fasting trial. On the contrary, there no alteration
of baseline cortisol concentration was detected in relation to
cycle phases in the meal intake trial and higher cortisol
levels after meal intake in all cortisol measurements.
Worthy of note, all data for this publication were not statis-
tically analyzed, as they were only mentioned as values
in graphics3.
Impact of MHT containing micronized progesterone on
the hypothalamic–pituitary–adrenal axis
Overall, only two RCTs investigated the impact of MHT con-
taining MP on the HPAA in healthy postmenopausal
women58,59 (Supplementary Table S2). The sample size
ranged from 1058 to 2559 participants, and mean age from
54.8 years58 to 57.5 years59, respectively. In both trials, inter-
ventions comprised a continuous combined MHT regimen
containing standard-dose estrogens (transdermal estradiol at
50 lg/day58,59, oral conjugated equine estrogens at 0.
625mg/day59) and oral MP at 100mg/day58,59. The duration
of the intervention ranged from 12weeks59 to 12months58.
Basal morning cortisol serum samples were analyzed by
radioimmunoassay at baseline and after 1month58,
3months58,59, 6months, 9months, and 12months58, respect-
ively. Compared to baseline, short-term MHT (3 months) did
not alter basal cortisol serum concentrations59, while 6
months of MHT significantly reduced basal cortisol serum
concentrations58.
Impact of progesterone on heart rate variability
Impact of endogenous progesterone exposure across the
menstrual cycle on heart rate variability
Of 21 hits, 12 studies evaluated the impact of endogenous P
exposure across the menstrual cycle on HRV3,6,10,21,22,60–66
(Supplementary Table S3). There were one systematic
review22, one RCT62, seven prospective observational cohort
studies3,6,10,61,64–66 and three comparative analyses21,60,63.
Sample size ranged from 73 to 10021 participants, and
mean age from 19.2 years66 to 48.8 years64 or age range from
18 to 37 years10,21,61, respectively. Women were generally
healthy and neither pregnant nor users of hormonal contra-
ception. One study compared perimenopausal women with
and without insomnia64, one study included women with
mild PMS66, and one study did not report subjects’ health
condition6. For inclusion into this review, HRV assessment
had to be performed at least once during the follicular phase
and once during the luteal phase of the menstrual cycle. The
majority of studies recorded HRV parameters for several
minutes3,10,21,60,62–64,66, while three performed 24-h electro-
cardiogram recordings6,61,65 or analyzed multiple time points
during different sleep stages64.
The first systematic review from 2016 analyzed 15 studies
on cardiac autonomic control with respect to the menstrual
Table 3. Literature search.
HPAA AND progesterone HPAA AND menstrual cycle HPAA AND HRT HRV AND progesterone HRV AND menstrual cycle HRV AND HRT
Hits (n) 137 81 72 5 21 5
Included articles (n) 7 19 2 1 12 0
HPAA, hypothalamic–pituitary–adrenal axis; HRT, hormone replacement therapy; HRV, heart rate variability.
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cycle22. Qualitative comparisons between the vast majority of
studies demonstrated a decrease of the vagal dominance on
the heart from the follicular to the luteal cycle phase.
More recent studies reported comparable results showing
overall a predominance of sympathetic activity in the luteal
phase3,6,10,21,60,61,66 and predominance of parasympathetic
activity in the follicular phase10,60, respectively. These find-
ings were in the majority independent of the subject’s pos-
ition (supine, seated, standing)60. Sleep deprivation has been
found to have an impact on cardiac autonomic control, dis-
playing a move to a predominance of parasympathetic activ-
ity after ovulation and a predominance of sympathetic
activity before ovulation63.
However, others did not find any significant differences in
cardiac autonomic control between different menstrual
cycle phases62,65.
Impact of MHT containing micronized progesterone on
heart rate variability
So far, there have not been any studies investigating the
impact of MHT containing estrogens combined with MP
on HRV.
Discussion
Stress activates the ANS and the HPAA. Sexual steroid hor-
mones have been found to modulate the stress response.
The aim of this systematic review was to specifically analyze
the impact of endogenous and exogenous exposure with
natural P on the stress response. Our systematic review
revealed that the HPAA activity was not relevantly affected
by endogenous P exposure across the menstrual cycle, but
might be reduced by exogenous MP application. In contrast,
the ANS has a sympathetic predominance in the (P-domi-
nated) luteal phase and parasympathetic predominance in
the follicular phase of the menstrual cycle, but has not yet
been evaluated under exogenous MP exposure.
Most studies did not observe an impact of endogenous P
exposure on baseline14,32–34,36,38,40,43,46–53,55 or
stimulated14,30,35,41,43,44,53,56,57 HPAA. However, few studies
reported higher baseline33,37,38 and stimulated28,36,39 cortisol
levels during the follicular phase, or vice versa3,29,39,45,54.
Varying results may be due to the type of specimen analyzed
(serum, saliva, urine) as differing results have been reported
when comparing salivary (no change) to 24-h urinary (higher
in the follicular phase) cortisol levels38, or salivary (higher in
the follicular phase) to serum (no change) cortisol levels33,
respectively. As cortisol is secreted in a circadian pattern, the
time point of sampling is crucial. For example, serum cortisol
levels have been found in a previous study to be higher dur-
ing the follicular phase than the luteal phase when compar-
ing samples taken at 8:00 a.m., while there was no difference
when comparing 3:00 p.m. samples across the cycle67. The
studies included in this review had a wide time spectrum for
sampling, or did not even mention it31,36,39,42,43.
Furthermore, as the individual menstrual cycle length
varies43, a defined cycle day for (serum, saliva, urine)
sampling may still yield different interpersonal and intraper-
sonal results. Serum cortisol levels are also affected by other
factors such as cortisol binding globulin serum levels or
comorbidities such as diabetes mellitus68 and mood disor-
ders69. Women recruited for the studies were characterized
to be healthy in general, yet differences in medication, body
weight, and lifestyle factors (physical activity, alcohol, diet)
and sleeping patterns that physiologically change across the
menstrual cycle may affect the stress response6. Finally, a
broad range of different methods to analyze cortisol levels
was applied. Two studies58,59 evaluated the impact of MHT
containing oral MP on the HPAA, with long-term MHT reduc-
ing basal serum cortisol levels. Besides duration of MHT
application, other factors such as estrogen type (estradiol,
conjugated equine estrogens) and mode of application (oral,
transdermal) may yield different results. Importantly, MP was
not studied as monotherapy but only in combination with
estrogens; thus, differentiating between the two sex steroids’
impact on cortisol levels was impossible.
With respect to ANS control, most studies reported a
parasympathetic dominance in the follicular phase or a sym-
pathetic dominance in the luteal phase of the menstrual
cycle6,10,21,60,61,63,64,66,70–81. This supports previous findings of
an increased prevalence of arrhythmias during the luteal
cycle phase82. Contradictory results by others might have
been due to certain study designs, for example sleep depriv-
ation63, or cohorts either differentiating between women
with and without PMS72,76,77,80,81 or not70,71,73–75,78,79,83–85.
Direct comparisons between studies were also impaired by
different HRV assessment methods including varying dur-
ation and time point of electrocardiogram recording. So far,
no study has reported the impact of MHT containing MP or
MP alone on HRV. As previous studies have reported a bene-
ficial effect of MHT on the stress response in postmeno-
pausal women22, which was even more pronounced with
combined MHT than estrogen-only therapy25, we would
expect a shift to a vagal tonus at least for MHT combined
with MP.
The strength of our review is the systematic literature
search differentiating between two stress biomarkers (HPAA,
HRV), and between endogenous and exogenous sex steroid
hormone exposure, and restriction to truly natural P expos-
ure. Clearly, our review also has some limitations such as
restriction to publications in English, and identification of
studies with only small sample sizes and mainly healthy
women. Thus, results might be different in bigger cohorts
and cannot be transferred to, for example, diseased individu-
als. Moreover, some data are mentioned without proof for
significance3,33,39,42,60. Finally, the results out of our review
cannot only be attributed to P itself, as the luteal phase is
characterized by high levels of both steroid hormones, estra-
diol and P43. Most interestingly, there have so far been no
studies combining the assessment of both stress biomarkers
across the menstrual cycle or when applying MHT, respect-
ively. In future, to obtain a broader picture of the impact of
steroid sex hormones on the stress response, it would be
preferable to assess various stress biomarkers at the same
time (e.g. questionnaires, basal and stimulated serum and
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salivary HPAA effectors, HRV under various conditions) to
also evaluate their relative impact.
Conclusion
Stress activates the ANS and the HPAA. Our systematic
review revealed that the HPAA activity was not relevantly
affected by endogenous P exposure across the menstrual
cycle, but might be reduced by exogenous MP application.
In contrast, the ANS has a sympathetic predominance in the
(P-dominated) luteal phase of the menstrual cycle. Future
studies should assess various stress biomarkers under various
hormonal conditions to, for example, allow for cardiovascular
disease risk stratification in hormone users.
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